초록 ▼

The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nit

The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.

대표청구항 ▼

The invention claimed is: 1. A device for transdermal delivery comprising a compound of the following Formula I: wherein A is hydrogen or deuterium, R is C1-6-alkyl, C3-10-cycloalkyl or phenyl, which may each be substituted with C1-3-alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hyd

The invention claimed is: 1. A device for transdermal delivery comprising a compound of the following Formula I: wherein A is hydrogen or deuterium, R is C1-6-alkyl, C3-10-cycloalkyl or phenyl, which may each be substituted with C1-3-alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium and where the C-atom marked with a star “*” is present in the (R)-configuration, and the compound of Formula I is present in a polymer matrix and can be released through the human skin in a dose of 0.5-20 mg per day. 2. A device of claim 1 wherein the device is produced by a process comprising adding a compound of Formula I in free base form to the polymer matrix. 3. A device of claim 1 wherein the polymer matrix incorporates 55-90 percent by weight of a contact adhesive and is self-adhesive. 4. A device of claim 1 wherein the polymer matrix incorporates one or more contact adhesives which are chosen from acrylates, ethylene vinyl acetates (EVA), silicones or styrene block copolymers (SXS). 5. A device of claim 1 wherein the polymer matrix comprises up to 50-95 percent by weight of a hot-meltable mixture of a silicone based contact adhesive and at least one softener. 6. A device according to claim 1 wherein the polymer matrix comprises up to 50-95 percent by weight from (a) a hydrophilic contact adhesive and/or (b) a mixture of a hydrophobic contact adhesive with 2-20 percent by weight, based on the total weight of the polymer matrix, of a hydrophilic polymer and/or (c) a mixture of a hydrophilic with a hydrophobic contact adhesive. 7. A device according to claim 6 whereby the hydrophilic polymer is PEG, PVP or PVAc. 8. A device of claim 1 wherein R is methyl, ethyl, isopropyl, 1-propyl, 1-butyl, 2-butyl, tertiary-butyl, iso-butyl, pentyl or hexyl. 9. A device of claim 1 wherein the compound is (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate (fesoterodine). 10. A device of claim 1 wherein the compound of the Formula I has been introduced into the polymer matrix in a degree of purity of above 97 percent by weight. 11. A device of claim 1 wherein the device: (a) exhibits a surface of a maximum 50 cm2; (b) comprises a self-adhesive polymer layer, which (b1) exhibits a weight of 30-300 g/m2, (b2) contains o by weight of a contact adhesive, (b3) contains a compound of Formula I in a concentration of 5-40 percent by weight based on the total weight of the polymer matrix; and (c) delivers the compound Formula I with a steady flux rate of at least 4 μg/cm2/hour through the human skin over a time period of at least 24 hours. 12. A device of claim 1 wherein the device exhibits a base area of a maximum of 40 cm, and the loading of the active ingredient of the self-adhesive polymer matrix amounts to 7-30 percent by weight. 13. A device of claim 1 wherein the device can transport a compound of the general Formula I in a dose of at least 3 mg per day over at least 24 hours at a constant flux rate through the human skin. 14. A device of claim 1 wherein the device comprises an adhesive matrix containing an active ingredient (1), a backing being impermeable and inert for the constituents of the adhesive matrix (2), and a protective layer detachable immediately before use (3). 15. A device for the transdermal delivery of the free base of (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate over a time period of at least 24 hours at a constant flux rate of at least 4 μg/cm2/hour, wherein said device comprises the free base of (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate. 16. A device of claim 1 wherein the device is a flat-shaped device for transdermal delivery of the matrix type where the compound of Formula I is present in a polymer layer or polymer paste.